Advertisement

The Latest

Patients with severe gastroesophageal reflux disease have lower rates of esophageal cancer than other GI patients because they are more likely to be screened for Barrett's esophagus, which can develop into cancer, according to a report in the Archives of…

The FDA has approved a risk evaluation and mitigation strategy for Cephalon's Fentora and Actiq drugs to manage breakthrough pain in opioid-tolerant patients with cancer, according to a Cephalon news release.

Advertisement